Targeted activation of this pathway can promote osteogenic differentiation, becoming a key mechanism for anti-osteoporosis therapy, such as natural compound therapy (55).With the continuous development of science and technology, researchers have found that miR-223-3p can block the activation of Wnt/β-Catenin signaling pathway by targeting the inhibition of FHL1 protein expression, thereby inhibiting the differentiation of BMSC into osteoblasts and ultimately accelerating the progression of osteoporosis (56). Here, FHL1 is linked to osteoporosis.